CA2348893A1 - Process for preparing cross-bridged tetraaza macrocycles - Google Patents

Process for preparing cross-bridged tetraaza macrocycles Download PDF

Info

Publication number
CA2348893A1
CA2348893A1 CA002348893A CA2348893A CA2348893A1 CA 2348893 A1 CA2348893 A1 CA 2348893A1 CA 002348893 A CA002348893 A CA 002348893A CA 2348893 A CA2348893 A CA 2348893A CA 2348893 A1 CA2348893 A1 CA 2348893A1
Authority
CA
Canada
Prior art keywords
formula
ligand
mixtures
methyl
tetraaza macrocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002348893A
Other languages
French (fr)
Inventor
George Douglas Ii Hiler
Christopher Mark Perkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22332328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2348893(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2348893A1 publication Critical patent/CA2348893A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic System
    • C07F13/005Compounds without a metal-carbon linkage
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/18Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
    • B01J31/1805Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
    • B01J31/181Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine
    • B01J31/1815Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine with more than one complexing nitrogen atom, e.g. bipyridyl, 2-aminopyridine
    • B01J31/182Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine with more than one complexing nitrogen atom, e.g. bipyridyl, 2-aminopyridine comprising aliphatic or saturated rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/70Complexes comprising metals of Group VII (VIIB) as the central metal
    • B01J2531/72Manganese
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/90Catalytic systems characterized by the solvent or solvent system used
    • B01J2531/96Water

Abstract

The present invention relates to a process for preparing a cross-bridged tetraaza macrocyclic ligand having formula (I) wherein each R is independent ly C1-C8 linear or branched alkyl, -(CH2)xCO2M, and mixtures thereof; provided both of the R units are not methyl; M is hydrogen or a salt forming cation; x is from 1 to 6; each index n is independently from 0 to 3; by contacting a d i- quaternary cis tetracycle precursor with hydrogen in the presence of a palladium catalyst in an aqueous solution having a pH of at least about 10 a t a temperature of about 40 ~C to about 100 ~C.

Description

WO 00!32601 PCT/US99/27316 PROCESS FOR PREPARING CROSS-BR)DGED
TETRAAZA MACROCYCLES
FIELD OF THE INVENTION
The present invention relates to an improved process for preparing cross-bridged tetraaza macrocycles, said macrocycles suitable as ligands for use in preparing transition metal complexes. The present invention provides a process which is well suited for use in industrial and other commercial preparations of the herein described crossed-bridged macrocycles.
BACKGROUND OF THE INVENTION
Tetraaza macrocyclics, for example, cyclam, have been prepared in numerous ways, however, there is a paucity of information relating to the preparation of cross-bridged tetraaza macrocyclics inter alia bis N-substituted tetraaza macrocyclics inter alia 5,12 dialkyl 1,5,8,12-tetraaza-bicyclo[6.6.2]hexadecanes which have recently found wide applicability as ligands especially in the area of transition metal catalysts inter alia bleach catalysts.
WO 98/39335 A1 "Improved Methods of Making Cross-Bridged Macropoly-cycles"
discloses a rational procedure for preparing cross bridged macropolycyclic ligands which is amenable to high yields necessary for industrial scale-up. However, the reductive ring cleavage step which results in bicyclo bridged-ring formation utilizes a borohydride reducing agent. This type of reducing agent can place constraints on the formulator. For example, the need to break up the amine/borohydride complex during work-up and the proper recovery and disposal of boron waste products adds cost to the process. Also, if excess borohydride is needed, this requires neutralization which involves the use of acid and the evolution of large quantities of hydrogen gas.
Therefore, a need exists for a highly quantitative, preferably catalytic, process for preparing cross-bridged macropolycyclic ligands which is adaptable to either continuous flow processes or batch preparations.
SUMMARY OF THE INVENTION
The present invention meets the aforementioned needs in that it has been surprisingly discovered that select bis N-substituted tetraaza macrocyclics can be converted to cross-bridged macropolycyclic ligands via catalytic hydrogenation.

A first aspect of the present invention relates to a process for preparing a tetraaza macrocyclic ligand having the formula:
(CHz~,~
~-N
(CH~~, R R {CHz~, ~N N
~ (~Hz~J
wherein each R is independently C,-C8 linear or branched alkyl, -(CH,)rCO~M, and mixtures thereof, preferably both of the R units are not methyl; M is hydrogen or a salt forming cation; x is from 1 to 6; each index n is independently from 0 to 3; said process comprising the steps of:
a) hydrogenating a tetraaza macrocyclic ligand precursor having the formula:
(CHz~, R
~N H N
(CHz~, (CHz~, \ / 2X-~N H N
R J
/ ~ (CHz~,~
wherein X is an anion which provides charge neutrality, with from about 1 ppm of a transition metal hydrogenation catalyst at a pH of at least $ to form a tetraaza macrocyclic ligand; and b) optionally isolating said ligand.
These and other objects, features, and advantages will become apparent to those of ordinary skill in the art from a reading of the following detailed description and the appended claims. All percentages, ratios and proportions herein are by weight, unless otherwise specified.
All temperatures are in degrees Celsius (o C) unless otherwise specified. All documents cited are in relevant pan, incorporated herein by reference.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to the catalytic hydrogenation of tetraaza macrocycles having the formula:

~(cH,~,~ /R
NI H IN
(CH~~, (CH=~, _ ~ / 2X
'-N H N
R
/ ~(CH.~,J
wherein the covalent bond between the N-substituted quaternary ring nitrogen and the bridging carbon is broken and a cross-bridged macrocyclic ligand having the formula:
(CH:~, ~--N i -~
(cH~~, R R (CH:~, ~N/ N
~ (~H~~J
is the resulting product.
In the above formula each R is independently C,-Ca linear or branched alkyl, -(CH,)rCO~M, and mixtures thereof, preferably both of the R units are not methyl; more preferably one R unit is methyl and the other R unit is selected from the group consisting of ethyl, propyl, butyl, pentyl, hexyl, and mixtures thereof of the methyl/alkyl R unit mixtures preferably one R is methyl and the other R is ethyl or propyl. A most preferred ligand consists of a unit wherein one R unit is methyl and the other R unit is ethyl. A preferred ligand is a macrocyclic ring wherein each R unit is ethyl. M is hydrogen or a salt forming cation, non-limiting examples of which are sodium, potassium, calcium, ammonium. When R is -(CH~)xCO~M the index x has the value from 1 to about 6, preferably x is 1. The index n defines the size of the macrocyclic ring. The index n has the value of from 0 to about 3. A preferred macrocyclic ring has one opposite set of n indices equal to 1 and the other set of n indices equal to 0 as in the general formula:

N N
R R
N N
wherein R is the same as defined herein above.
Preferred ligands according to the present invention comprise R unit pairs which are selected from the group consisting of methyl and ethyl, diethyl, methyl and propyl, ethyl and propyl, methyl and butyl. ethyl and butyl, and mixtures thereof.
The starting materials for the process of the present invention are tetraaza macrocyclic ligand precursors, or alternatively, bis-quaternary cis tetracycles, having the formula:
(CH:~, R
~N H N
~+
(CFiz~, (CHz~, 2 X -'--.- N H N
R
~ (~H~~J
wherein R and n are the same as defined herein above. X is an anion which serves to provide electronic neutrality to the bis-quaternary cis tetracycle. Those of ordinary skill in the art recognize that the term "electronic neutrality" refers to "a sufficient amount of an anionic species which satisfies the molecular charge balance requirements" and that a mixture of mono-, di-, tri-.
etc. electronic species may be use herein. X preferably has unit negative charge, for example, 1 S halogen, tosylate, methylsulfate, ethylsulfate. However, X may have more than one negative charge, for example, sulfate, in which case the formulator requires only half the amount necessary when using a unit negative-charged anion. Preferred X is chloride, bromide, iodide, sulfate, ethyl sulfate, methyl sulfate, tosylate, mesylate, triflate, and mixtures thereof.
STEP (a) Hydrogenation - Reductive Cleavage Step (a) comprises the reductive cleavage via catalytic hydrogenation as outlined in the following scheme:

(CH=~, ~ ~ (CH=~, R
~N H N
/~ N N
(CH=~, fCH=~, H~ (C~ R R ~ H:~
, / 2X- /
~N H N~ catalyst ~N/ y R
(CH~~,~
(CH=~,~
wherein the cis-tetracycle bis quaternary salt is converted to the cross-bridged tetraaza macrocycle.
3 Step (a) is conducted in the presence of a catalyst, preferably a supported catalyst. Non-limiting examples of catalysts include platinum on carbon, palladium on carbon (Pd/C), palladium hydroxide on carbon (Pd(OH),iC), rhodium on carbon (Rh/C), Raney nickel, and mixtures thereof. A preferred catalyst is Pd(OH)Z/C. The supported catalysts may comprise from about 1% to about 50% by weight of transition metal, however, the pure metal, i.e. palladium, can be used without the need for a "support", i.e., carbon. A "catalytic amount"
of catalyst is sufficient to provide the reduction of step (a). For the purposes of the present invention the term catalytic amount is defined as "from about 1 ppm of a S% by weight transition metal catalyst".
However, the formulator, due to poisoning of the catalyst surface by reaction products may use more than a catalytic amount of a catalyst. The amount of catalyst used in step (a) of the present invention is preferably from about 10 ppm of a catalyst which contains from about 5% to 50% by weight, of a transition metal, more preferably from about 100 ppm, yet more preferably from about 0.1% by weight, of a transition metal supported catalyst. A reaction solution which comprises 0.1% by weight, of a transition metal supported catalyst, said catalyst comprising, for example, 10% by weight.of palladium on carbon, has 0.01 % transition metal or 100 ppm transition metal present.
The amount of hydrogen gas present in step (a) of the present invention need only be enough to sufficiently saturate the catalyst surface, preferably the hydrogen pressure is from 200 psi, more preferably from 400 psi, most preferably from 800 psi to about 2000 psi, more preferably to 1000 psi.
Step (a) of the present process can be conducted at a temperature of from 20° C, preferably from about 40° C, more preferably from about 60° C to about 100° C, preferably to about 90° C, more preferably to about 80° C, most preferably to about 65° C.

The pH under which Step (a) must be conducted is at least 8, preferably at least 10, more preferably at least about 11. Preferably the base which is used to adjust the pH is in the form of an aqueous solution. Preferred bases are selected from the group consisting of potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, and mixtures thereof. As a non-limiting example, it is satisfactory to use a sufficient amount of 1 M
(molar) aqueous base to adjust the pH to the required level. A convenient and preferred base is potassium carbonate.
As a suitable alternative, Step (a) can be conducted in the presence of a solvent other than water, or in the absence of water. A mixture of a suitable solvent and water is a suitable means for conducting the hydrogenation process of the present invention. In the case where water is absent, sufficient base must be present to stabilize the transition state of the reactants and products during hydrogenation. Non-limiting examples of solvents include methanol, ethanol, n-propanol, isopropanol, N,N-dimethyl formamide, n-butanol, iso-butanol, tert-butanol, and mixtures thereof; preferred solvents are selected from the group consisting of ethanol, n-propanol, N,N-dimethyl formamide, and mixtures thereof. VVhen a solvent is present and the base is in the form of an aqueous solution, the ratio of said volume of an aqueous base, to said solvent is from about 1:10 to about 1:1, preferably the ratio of the volume of aqueous base to solvent is 1:4. It is desirable, but not a requirement, that the aqueous base and solvent form a two phase system.
The process of the present invention comprises an optional, although preferred, Step (b) which is an isolation step. Typically this step involves filtration of the reaction solution to remove the catalyst. In addition, this step may comprise a neutralization step, however, the product can be isolated or removed from the reaction matrix in any manner which the formulator desires.
When filtration of the catalyst is a desired step, the reaction solution containing the cross-bridged ligand is filtered to remove the catalyst to form a crude filtrate.
This crude filtrate can be neutralized or the tetraaza macrocyclic ligand can be isolated by extraction or crystallization directly from the preferably aqueous solution.
Steps {a) and (b) and any optional extensions thereto, for example, a crystallization step, a solvent drying step, a purging step, may be suitably adapted for either batch processes or continuous processes, for example, continuous flow processes. As mentioned herein, the process of the present invention may comprise other optional steps as deemed necessary and/or desirable by the formulator. These optional steps may include but are not limited to, pre-saturation of the catalyst with hydrogen, drawing a vacuum on the system, and recovery of the catalyst and solvents.

Preferably the ligands formed by the process of the present invention are converted into manganese containing transition metal catalysts in a subsequent, however optional, process step.
The bleach catalysts comprise a central manganese atom and a cross-branched ligand formed by the process of the present invention. The final bleach catalyst may comprise one or more other compatible ligands inter alia chlorine atom. The preferred catalysts are suitable as bleaching agents.
The following is a non-limiting example of the process of the present invention.
Preparation of 5,12-diethyl-1,5,8,12-tetraaza-bicvclo(6.6.21hexadecane To a thick walled, glass autoclave sleeve is added the bis-quaternary cis tetracycle having the formula:
~ HzCH3 N H N
2 Br -N H N

(3.0 g, 6.8 mmol) and a 1M aqueous solution of KZC03 (30 mL). The solution is agitated to dissolve the substrate then 20°.o Pd(OH)~/carbon (0.7 g, 1.0 mmol) is added. The glass sleeve is placed into a rocking autoclave and hydrogenated at 65° C with 1900 psig hydrogen for 4 hours.
The reaction is cooled and the solution filtered through glass fiber filter paper to remove the catalyst and the filtrate is reduced to a white solid under vacuum. The white solid is suspended in refluxing ethanol and the un-dissolved inorganic salts are collected by filtration. After concentrating the filtrate under vacuum, the resulting oily residue is dissolved in aqueous 4M
KOH (4 mL) and extracted three times with 25 mL portions of toluene. The toluene extracts are combined and concentrated in vacuo to afford 5,12-diethyl-1,5,8,12-tetraaza-bicyclo[6.6.2Jhexadecane (1.56 g) in 81% yield as a clear oil.
The following is an example of an optional, but preferred step of the process of the present invention which is conversion to a manganese transition metal bleach catalyst.
Preparation of dichloro 5,12-diethyl-1,5,8,12-tetraaza-bicvclof6.6.Zlhexadecane maneanese To a 100 mL reaction flask is charged anhydrous acetonitrile (50 mL) and 5,12-diethyl-1,5,8,12-tetraaza-bicyclo[6.6.2]hexadecane (1.4 g, 5 mmol). The resulting suspension is degassed under vacuum with subsequent re-filling with argon. This process is repeated six times.
Manganese(II) chloride (0.590 g, 4.7 mmol) is added and the reaction is refluxed for 3 hours.

The resulting solution is filtered through glass-fiber filter paper. The resulting filtrate is concentrated under reduced pressure at 45° C to afford a solid. The solid is suspended in toluene (~0 mL) and the resulting dark supernatant is discarded. Treatment with toluene is repeated five times. The resulting solid is dried under vacuum to yield dichloro 5,12-diethyl-1,5,8,12-tetraaza-bicyclo[6.6.2]hexadecane manganese (1.48 g, 73% yield).

Claims (12)

WHAT IS CLAIMED IS:
1. A process for preparing a tetraaza macrocyclic ligand having the formula:
wherein each R is independently C1-C8 linear or branched alkyl, -(CH2)x CO2M, and mixtures thereof, provided both of the R units are not methyl; M is hydrogen or a salt forming cation; x is from 1 to 6; each index n is independently from 0 to 3;
said process comprising the steps of:
a) hydrogenating a tetraaza macrocyclic ligand precursor having the formula:
wherein X- is an anion which provides charge neutrality, with from 1 ppm of a transition metal hydrogenation catalyst at a pH of at least 8 to form a tetraaza macrocyclic ligand; and b) optionally isolating said ligand.
2. A process according to Claim 1 wherein said transition metal hydrogenation catalyst is selected from the group consisting of platinum, palladium, palladium hydroxide, rhodium, Raney nickel, and mixtures thereof.
3. A process according to either of Claims 1 or 2 wherein step (a) is conducted at a temperature of from 40° C to 100° C, at a pH of at least 10, and in the presence of a solvent, said solvent selected from the group consisting of water, N,N-dimethyl formamide, methanol, ethanol, isopropanol, n-butanol, iso-butanol, tert-butanol, and mixtures thereof.
4. A process according any of Claims 1-3 wherein said precursor has the formula:
wherein R and X are the same as defined herein above.
5. A process according to any of Claims 1-4 wherein each R is ethyl.
6. A process according to any of Claims 1-5 wherein one R is methyl and one R
is ethyl.
7. A process for preparing a tetraaza macrocyclic ligand having the formula:
wherein one R unit is methyl and the other R unit is selected from the group consisting of ethyl, propyl, butyl, pentyl, hexyl, and mixtures thereof; said process comprising the steps of:
a) hydrogenating a tetraaza macrocyclic ligand precursor having the formula:

wherein X - is an anion which provides charge neutrality, with from 1 ppm of a palladium hydrogenation catalyst at a pH of at least 10 to form a tetraaza macrocyclic ligand; and b) optionally isolating said ligand.
8. A process for preparing a tetraaza macrocyclic ligand having the formula;
wherein each R is independently C1-C8 linear or branched alkyl, -(CH2)x CO2M, and mixtures thereof, provided both of the R units are not methyl; M is hydrogen or a salt forming cation; x is from 1 to 6; each index n is independently from 0 to 3;
said process comprising the steps of:
a) hydrogenating a tetraaza macrocyclic ligand precursor having the formula:
wherein X - is an anion which provides charge neutrality, with from 1 ppm of a palladium hydrogenation catalyst, said palladium catalyst selected from the group consisting of supported palladium(0), palladium hydroxide, and mixtures thereof; at a pH of at least 8; in the presence of a solvent, said solvent selected from the group consisting of water, methanol, ethanol, N,N-dimethyl formamide, n-butanol, iso-butanol, tert-butanol, and mixture thereof; at a temperature of from 0° C to 100° C; to form a tetraaza macrocyclic ligand; and b) removing the catalyst by filtration to form a crude filtrate;
c) optionally isolating said ligand by crystallizing, extracting, distilling, or other suitable means.
9. A process according to Claim 8 wherein said process further comprises the step of treating said ligand with manganese to form a cross-bridged tetraaza macrocyclic transition metal catalyst.
10. A process for preparing a tetraaza macrocyclic ligand having the formula:
wherein R units are R unit pairs selected from the group consisting of methyl and ethyl, diethyl, methyl and propyl, ethyl and propyl, methyl and butyl, ethyl and butyl, and mixtures thereof; M is hydrogen or a salt forming canon; x is from 1 to 6;
each index n is independently from 0 to 3; said process comprising the steps of:
a) hydrogenating a tetraaza macrocyclic ligand precursor having the formula:
wherein X - is an anion which provides charge neutrality, with from 1 ppm of a transition metal hydrogenation catalyst at a pH of at least 8 to form a tetraaza macrocyclic ligand; and b) optionally isolating said ligand.
11. A transition metal catalyst comprising:
a) a crossed-bridged ligand having the formula:
wherein each R is independently C1-C8 linear or branched alkyl, -(CH2)x CO2M, and mixtures thereof, provided both of the R units are not methyl or butyl; M
is hydrogen or a salt forming cation; x is from 1 to 6; each index n is independently from 0 to 3;
b) manganese; and c) optionally one or more compatible ligands.
12. A compound according to Claim 11 having the formula:
CA002348893A 1998-11-30 1999-11-18 Process for preparing cross-bridged tetraaza macrocycles Abandoned CA2348893A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11030998P 1998-11-30 1998-11-30
US60/110,309 1998-11-30
PCT/US1999/027316 WO2000032601A2 (en) 1998-11-30 1999-11-18 Process for preparing cross-bridged tetraaza macrocycles

Publications (1)

Publication Number Publication Date
CA2348893A1 true CA2348893A1 (en) 2000-06-08

Family

ID=22332328

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002348893A Abandoned CA2348893A1 (en) 1998-11-30 1999-11-18 Process for preparing cross-bridged tetraaza macrocycles

Country Status (5)

Country Link
EP (1) EP1135392A2 (en)
JP (1) JP2002531457A (en)
AU (1) AU2026100A (en)
CA (1) CA2348893A1 (en)
WO (1) WO2000032601A2 (en)

Families Citing this family (252)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509924A (en) * 2000-09-25 2004-04-02 ザ、プロクター、エンド、ギャンブル、カンパニー MRI image enhancing composition
FR2830253B1 (en) 2001-09-28 2005-02-04 Air Liquide NOVEL PROCESS FOR THE PREPARATION OF C-FUNCTIONALIZED NITROGEN MACROCYCLES AND NOVEL INTERMEDIATES OBTAINED
US7169744B2 (en) 2002-06-06 2007-01-30 Procter & Gamble Company Organic catalyst with enhanced solubility
US7557076B2 (en) 2002-06-06 2009-07-07 The Procter & Gamble Company Organic catalyst with enhanced enzyme compatibility
FR2856063B1 (en) * 2003-06-13 2005-10-07 Air Liquide PROCESS FOR THE PREPARATION OF CIS-8B-METHYLDECAHYDRO-2A, 4A, 6A, 8A-TETRAAZACYCLOPENTA [FG] ACENAPHTHYLENE, OR CIS-DECAHYDRO-2A, 4A, 6A, 8A-TETRAAZACYCLOPENTA [FG] ACENAPHTHYLENE, CYCLENE, AND CYCLENES FUNCTIONALISED
US8535927B1 (en) 2003-11-19 2013-09-17 Danisco Us Inc. Micrococcineae serine protease polypeptides and compositions thereof
US7985569B2 (en) 2003-11-19 2011-07-26 Danisco Us Inc. Cellulomonas 69B4 serine protease variants
EP2664670B1 (en) 2003-12-03 2015-05-06 Danisco US Inc. Perhydrolase
US20050181969A1 (en) 2004-02-13 2005-08-18 Mort Paul R.Iii Active containing delivery particle
US7425527B2 (en) 2004-06-04 2008-09-16 The Procter & Gamble Company Organic activator
US7686892B2 (en) 2004-11-19 2010-03-30 The Procter & Gamble Company Whiteness perception compositions
AR051659A1 (en) 2005-06-17 2007-01-31 Procter & Gamble A COMPOSITION THAT INCLUDES AN ORGANIC CATALYST WITH IMPROVED ENZYMATIC COMPATIBILITY
ES2415872T3 (en) 2005-08-19 2013-07-29 The Procter & Gamble Company Solid laundry detergent composition comprising an anionic detersive surfactant and calcium enhancement technology
US20070044824A1 (en) 2005-09-01 2007-03-01 Scott William Capeci Processing system and method of processing
JP2009509750A (en) 2005-09-27 2009-03-12 ザ・プロクター・アンド・ギャンブル・カンパニー Microcapsule and manufacturing method thereof
US20080293610A1 (en) 2005-10-12 2008-11-27 Andrew Shaw Use and production of storage-stable neutral metalloprotease
BRPI0617738A2 (en) 2005-10-24 2011-08-02 Procter & Gamble tissue treatment compositions and systems comprising organosilicone microemulsions, and methods for using them
EP2248882A1 (en) 2006-01-23 2010-11-10 The Procter and Gamble Company Enzyme and fabric hueing agent containing compositions
US7790666B2 (en) 2006-01-23 2010-09-07 The Procter & Gamble Company Detergent compositions
MX2008011072A (en) 2006-02-28 2008-09-05 Procter & Gamble Benefit agent containing delivery particle.
US7629158B2 (en) 2006-06-16 2009-12-08 The Procter & Gamble Company Cleaning and/or treatment compositions
WO2008016637A1 (en) 2006-08-01 2008-02-07 Appleton Papers Inc. Benefit agent containing delivery particle
JP2010509447A (en) 2006-11-22 2010-03-25 ザ プロクター アンド ギャンブル カンパニー Beneficial agent-containing delivery particles
US20080177089A1 (en) 2007-01-19 2008-07-24 Eugene Steven Sadlowski Novel whitening agents for cellulosic substrates
MX2009008790A (en) 2007-02-15 2009-08-24 Procter & Gamble Benefit agent delivery compositions.
EP2155844B1 (en) 2007-06-05 2012-11-21 The Procter & Gamble Company Perfume systems
EP2160176B1 (en) 2007-06-11 2017-07-26 The Procter and Gamble Company Benefit agent containing delivery particle
US8021436B2 (en) 2007-09-27 2011-09-20 The Procter & Gamble Company Cleaning and/or treatment compositions comprising a xyloglucan conjugate
US20090094006A1 (en) 2007-10-03 2009-04-09 William David Laidig Modeling systems for consumer goods
CN101868538B (en) 2007-11-01 2013-07-10 丹尼斯科美国公司 Production of thermolysin and variants thereof and use in liquid detergents
EP2071017A1 (en) 2007-12-04 2009-06-17 The Procter and Gamble Company Detergent composition
EP2242829B1 (en) 2008-01-04 2013-03-13 The Procter & Gamble Company Laundry detergent composition comprising a glycosyl hydrolase and a benefit agent containing delivery particle
CA2709609C (en) 2008-01-04 2013-05-28 The Procter & Gamble Company Glycosyl hydrolase enzyme and fabric hueing agent containing compositions
EP2083065A1 (en) 2008-01-22 2009-07-29 The Procter and Gamble Company Colour-Care Composition
WO2009102755A1 (en) 2008-02-11 2009-08-20 Danisco Us Inc., Genencor Division Enzyme with microbial lysis activity from trichoderma reesei
AU2009214868A1 (en) 2008-02-14 2009-08-20 Danisco Us Inc. Small enzyme-containing granules
US20090209447A1 (en) 2008-02-15 2009-08-20 Michelle Meek Cleaning compositions
US7923426B2 (en) 2008-06-04 2011-04-12 The Procter & Gamble Company Detergent composition
CA2726370A1 (en) 2008-06-06 2009-12-10 Danisco Us Inc. Compositions and methods comprising variant microbial proteases
EP2272941B1 (en) 2008-06-20 2013-08-14 The Procter & Gamble Company Laundry composition
EP2135933B1 (en) 2008-06-20 2013-04-03 The Procter and Gamble Company Laundry composition
BRPI0916612A2 (en) 2008-07-30 2015-11-10 Procter & Gamble Comapny release particle
EP2166077A1 (en) 2008-09-12 2010-03-24 The Procter and Gamble Company Particles comprising a hueing dye
EP2166078B1 (en) 2008-09-12 2018-11-21 The Procter & Gamble Company Laundry particle made by extrusion comprising a hueing dye
EP2163608A1 (en) 2008-09-12 2010-03-17 The Procter & Gamble Company Laundry particle made by extrusion comprising a hueing dye and fatty acid soap
WO2010053940A1 (en) 2008-11-07 2010-05-14 The Procter & Gamble Company Benefit agent containing delivery particle
WO2010056634A1 (en) 2008-11-11 2010-05-20 Danisco Us Inc. Compositions and methods comprising a subtilisin variant
BR122013014156A2 (en) 2008-11-11 2015-07-14 Danisco Us Inc Cleaning composition comprising subtilisin variants as well as cleaning process
CN102209777B (en) 2008-11-11 2014-02-12 丹尼斯科美国公司 Compositions and methods comprising subtilisin variant
BR122013014157A2 (en) 2008-11-11 2018-11-13 Danisco Us Inc. cleaning compositions comprising bacillus subtilisin variants as well as cleaning process
MX2011005801A (en) 2008-12-01 2011-06-20 Procter & Gamble Perfume systems.
US8754028B2 (en) 2008-12-16 2014-06-17 The Procter & Gamble Company Perfume systems
CN102361965A (en) 2009-04-02 2012-02-22 宝洁公司 Composition comprising delivery particles
WO2011002476A1 (en) 2009-06-30 2011-01-06 The Procter & Gamble Company Fabric care compositions comprising cationic polymers and amphoteric
US20100325812A1 (en) 2009-06-30 2010-12-30 Rajan Keshav Panandiker Rinse Added Aminosilicone Containing Compositions and Methods of Using Same
US20110005001A1 (en) 2009-07-09 2011-01-13 Eric San Jose Robles Detergent Composition
CN102471731A (en) 2009-07-10 2012-05-23 宝洁公司 Compositions containing benefit agent delivery particles
WO2011005932A1 (en) 2009-07-10 2011-01-13 The Procter & Gamble Company Compositions containing benefit agent delivery particles
CN102471733A (en) 2009-07-27 2012-05-23 宝洁公司 Detergent composition
EP3255135B1 (en) 2009-11-06 2019-01-02 The Procter & Gamble Company High-efficiency perfume capsules
CN102762222B (en) 2009-12-09 2015-11-25 丹尼斯科美国公司 Comprise compositions and the method for ease variants
WO2011072117A1 (en) 2009-12-09 2011-06-16 The Procter & Gamble Company Fabric and home care products
MX323219B (en) 2009-12-18 2014-08-28 Procter & Gamble Perfumes and perfume encapsulates.
WO2011075556A1 (en) 2009-12-18 2011-06-23 The Procter & Gamble Company Composition comprising encapsulates, and process for making them
WO2011084599A1 (en) 2009-12-21 2011-07-14 Danisco Us Inc. Detergent compositions containing bacillus subtilis lipase and methods of use thereof
US20120258507A1 (en) 2009-12-21 2012-10-11 Danisco Us Inc. Detergent compositions containing thermobifida fusca lipase and methods of use thereof
US8741609B2 (en) 2009-12-21 2014-06-03 Danisco Us Inc. Detergent compositions containing Geobacillus stearothermophilus lipase and methods of use thereof
MX2012008498A (en) 2010-01-21 2012-08-17 Procter & Gamble Process of preparing a particle.
US20110201537A1 (en) 2010-02-12 2011-08-18 Jennifer Beth Ponder Benefit compositions comprising crosslinked polyglycerol esters
US20110201533A1 (en) 2010-02-12 2011-08-18 Jennifer Beth Ponder Benefit compositions comprising polyglycerol esters
US20110201534A1 (en) 2010-02-12 2011-08-18 Jennifer Beth Ponder Benefit compositions comprising polyglycerol esters
WO2011100420A1 (en) 2010-02-12 2011-08-18 The Procter & Gamble Company Benefit compositions comprising crosslinked polyglycerol esters
WO2011109322A1 (en) 2010-03-04 2011-09-09 The Procter & Gamble Company Detergent composition
JP6018044B2 (en) 2010-04-15 2016-11-02 ダニスコ・ユーエス・インク Compositions and methods comprising protease variants
MX2012012242A (en) 2010-04-19 2012-11-23 Procter & Gamble Detergent composition.
US9186642B2 (en) 2010-04-28 2015-11-17 The Procter & Gamble Company Delivery particle
US9993793B2 (en) 2010-04-28 2018-06-12 The Procter & Gamble Company Delivery particles
HUE045202T2 (en) 2010-05-06 2019-12-30 Procter & Gamble Consumer products with protease variants
BR112012029188B1 (en) 2010-05-18 2020-12-08 Milliken & Company optical whitening compounds and compositions comprising the same
CN102906239B (en) 2010-05-18 2015-09-09 美利肯公司 White dyes and containing its composition
BR112012030525A2 (en) 2010-05-26 2016-08-09 Procter & Gamble encapsulated
WO2011150157A2 (en) 2010-05-28 2011-12-01 Danisco Us Inc. Detergent compositions containing streptomyces griseus lipase and methods of use thereof
US8476216B2 (en) 2010-05-28 2013-07-02 Milliken & Company Colored speckles having delayed release properties
EP2585568A1 (en) 2010-06-22 2013-05-01 The Procter and Gamble Company Perfume systems
CA2799582C (en) 2010-06-22 2017-01-03 The Procter & Gamble Company Perfume systems
EP2588587B1 (en) 2010-06-30 2018-08-22 The Procter and Gamble Company Rinse added aminosilicone containing compositions and methods of using same
CA2803685C (en) 2010-07-20 2015-05-05 The Procter & Gamble Company Delivery particles with a plurality of cores
MX2013000792A (en) 2010-07-20 2013-02-27 Procter & Gamble Particles with a plurality of coatings.
CA2810534C (en) 2010-09-20 2017-04-18 The Procter & Gamble Company Non-fluoropolymer surface protection composition
JP2013538282A (en) 2010-09-20 2013-10-10 ザ プロクター アンド ギャンブル カンパニー Non-fluoropolymer surface protection composition
BR112013004895B1 (en) 2010-09-20 2021-07-06 Wacker Chemie Ag fabric care composition and method of providing stain repellency to a textile product
WO2012057781A1 (en) 2010-10-29 2012-05-03 The Procter & Gamble Company Cleaning and/or treatment compositions comprising a fungal serine protease
WO2011026154A2 (en) 2010-10-29 2011-03-03 The Procter & Gamble Company Cleaning and/or treatment compositions
US8715368B2 (en) 2010-11-12 2014-05-06 The Procter & Gamble Company Thiophene azo dyes and laundry care compositions containing the same
ES2436268T3 (en) 2010-12-21 2013-12-30 Procter & Gamble International Operations Sa Encapsulated
WO2012116021A1 (en) 2011-02-25 2012-08-30 Milliken & Company Capsules and compositions comprising the same
JP6283607B2 (en) 2011-04-07 2018-02-21 ザ プロクター アンド ギャンブル カンパニー Personal cleansing composition with increased deposition of polyacrylate microcapsules
US8980292B2 (en) 2011-04-07 2015-03-17 The Procter & Gamble Company Conditioner compositions with increased deposition of polyacrylate microcapsules
MX2013010983A (en) 2011-04-07 2013-10-30 Procter & Gamble Shampoo compositions with increased deposition of polyacrylate microcapsules.
EP2697352A1 (en) 2011-04-12 2014-02-19 The Procter and Gamble Company Metal bleach catalysts
US20140135252A1 (en) 2011-04-29 2014-05-15 Danisco Us Inc. Detergent compositions containing geobacillus tepidamans mannanase and methods of use thereof
US8802388B2 (en) 2011-04-29 2014-08-12 Danisco Us Inc. Detergent compositions containing Bacillus agaradhaerens mannanase and methods of use thereof
BR112013026675A2 (en) 2011-04-29 2016-11-29 Danisco Us Inc detergent compositions containing bacillus sp. mannanase, and methods of use thereof
BR112013027963A2 (en) 2011-05-05 2016-11-29 Danisco Us Inc "Subtilisin variant with proteolytic activity, nucleic acid, expression vector, host cell, composition and cleaning method".
MX357386B (en) 2011-05-05 2018-07-06 Procter & Gamble Compositions and methods comprising serine protease variants.
US20140371435A9 (en) 2011-06-03 2014-12-18 Eduardo Torres Laundry Care Compositions Containing Thiophene Azo Dyes
EP2537918A1 (en) 2011-06-20 2012-12-26 The Procter & Gamble Company Consumer products with lipase comprising coated particles
AR086558A1 (en) 2011-06-23 2014-01-08 Procter & Gamble PERFUME SYSTEM
JP5948417B2 (en) 2011-08-10 2016-07-06 ザ プロクター アンド ギャンブル カンパニー Inclusion body
BR112014004444A2 (en) 2011-08-31 2017-03-21 Danisco Us Inc compositions and methods comprising a lipolytic enzyme variant
CN103874758A (en) 2011-09-13 2014-06-18 宝洁公司 Encapsulates
EP2581438A1 (en) 2011-10-12 2013-04-17 The Procter and Gamble Company Detergent composition
BR112014014410A2 (en) 2011-12-22 2019-09-24 Danisco Us Inc compositions and methods comprising a lipolytic enzyme variant
EP3109309B1 (en) 2012-01-18 2022-06-08 The Procter & Gamble Company Perfume systems
MX353911B (en) 2012-02-03 2018-02-02 Novozymes As Lipase variants and polynucleotides encoding same.
MX353896B (en) 2012-02-03 2018-02-01 Procter & Gamble Compositions and methods for surface treatment with lipases.
IN2014DN07763A (en) 2012-03-19 2015-05-15 Milliken & Co
WO2013148639A1 (en) 2012-03-26 2013-10-03 The Procter & Gamble Company Cleaning compositions comprising ph-switchable amine surfactants
CN104204198B (en) 2012-04-02 2018-09-25 诺维信公司 Lipase Variant and the polynucleotides for encoding it
CN104302753A (en) 2012-05-16 2015-01-21 诺维信公司 Compositions comprising lipase and methods of use thereof
EP2674475A1 (en) 2012-06-11 2013-12-18 The Procter & Gamble Company Detergent composition
US9796952B2 (en) 2012-09-25 2017-10-24 The Procter & Gamble Company Laundry care compositions with thiazolium dye
EP2712915A1 (en) 2012-10-01 2014-04-02 The Procter and Gamble Company Methods of treating a surface and compositions for use therein
CN105026541A (en) 2012-10-04 2015-11-04 艺康美国股份有限公司 Pre-soak technology for laundry and other hard surface cleaning
CN110093330B (en) 2012-10-12 2023-11-28 丹尼斯科美国公司 Compositions and methods comprising lipolytic enzyme variants
US9095787B2 (en) 2012-10-24 2015-08-04 The Procter & Gamble Company Compositions comprising anti-foams
US9133421B2 (en) 2012-10-24 2015-09-15 The Procter & Gamble Company Compositions comprising anti-foams
CN104781400A (en) 2012-11-05 2015-07-15 丹尼斯科美国公司 Compositions and methods comprising thermolysin protease variants
WO2014100018A1 (en) 2012-12-19 2014-06-26 Danisco Us Inc. Novel mannanase, compositions and methods of use thereof
ES2652301T3 (en) 2013-03-05 2018-02-01 The Procter & Gamble Company Mixed sugar-based amide surfactant compositions
CN105051174B (en) 2013-03-21 2018-04-03 诺维信公司 Polypeptide and their polynucleotides of coding with lipase active
US10351833B2 (en) 2013-05-14 2019-07-16 Novozymes A/S Detergent compositions
US20140338134A1 (en) 2013-05-20 2014-11-20 The Procter & Gamble Company Encapsulates
EP2806018A1 (en) 2013-05-20 2014-11-26 The Procter & Gamble Company Encapsulates
JP6077177B2 (en) 2013-05-28 2017-02-08 ザ プロクター アンド ギャンブル カンパニー Surface treatment composition containing photochromic dye
EP3004314B1 (en) 2013-05-29 2018-06-20 Danisco US Inc. Novel metalloproteases
US20160108387A1 (en) 2013-05-29 2016-04-21 Danisco Us Inc. Novel metalloproteases
EP3882346A1 (en) 2013-05-29 2021-09-22 Danisco US Inc. Novel metalloproteases
EP3110833B1 (en) 2013-05-29 2020-01-08 Danisco US Inc. Novel metalloproteases
WO2015004102A1 (en) 2013-07-09 2015-01-15 Novozymes A/S Polypeptides with lipase activity and polynucleotides encoding same
EP3696264B1 (en) 2013-07-19 2023-06-28 Danisco US Inc. Compositions and methods comprising a lipolytic enzyme variant
EP3044313B1 (en) 2013-09-12 2019-11-06 Danisco US Inc. Compositions and methods comprising lg12-clade protease variants
US9834682B2 (en) 2013-09-18 2017-12-05 Milliken & Company Laundry care composition comprising carboxylate dye
CA2921433A1 (en) 2013-09-18 2015-03-26 The Procter & Gamble Company Laundry care composition comprising carboxylate dye
WO2015042209A1 (en) 2013-09-18 2015-03-26 The Procter & Gamble Company Laundry care compositions containing thiophene azo carboxylate dyes
CA2921432A1 (en) 2013-09-18 2015-03-26 The Procter & Gamble Company Laundry care composition comprising carboxylate dye
ES2723948T3 (en) 2013-12-13 2019-09-04 Danisco Us Inc Serine proteases from Bacillus species
EP3910057A1 (en) 2013-12-13 2021-11-17 Danisco US Inc. Serine proteases of the bacillus gibsonii-clade
EP3097173B1 (en) 2014-01-22 2020-12-23 The Procter and Gamble Company Fabric treatment composition
WO2015112341A1 (en) 2014-01-22 2015-07-30 The Procter & Gamble Company Fabric treatment composition
WO2015112340A1 (en) 2014-01-22 2015-07-30 The Procter & Gamble Company Method of treating textile fabrics
WO2015112338A1 (en) 2014-01-22 2015-07-30 The Procter & Gamble Company Method of treating textile fabrics
CN106103721B (en) 2014-03-12 2020-01-03 诺维信公司 Polypeptides having lipase activity and polynucleotides encoding same
CN106170546A (en) 2014-03-21 2016-11-30 丹尼斯科美国公司 The serine protease of bacillus
EP3131921B1 (en) 2014-04-15 2020-06-10 Novozymes A/S Polypeptides with lipase activity and polynucleotides encoding same
WO2015171592A1 (en) 2014-05-06 2015-11-12 Milliken & Company Laundry care compositions
WO2015181118A1 (en) 2014-05-27 2015-12-03 Novozymes A/S Methods for producing lipases
US10023852B2 (en) 2014-05-27 2018-07-17 Novozymes A/S Lipase variants and polynucleotides encoding same
WO2016049397A1 (en) 2014-09-26 2016-03-31 The Procter & Gamble Company Freshening compositions and devices comprising same
DK3207129T3 (en) 2014-10-17 2020-02-24 Danisco Us Inc SERIN PROTEAS OF THE BACILLUS ART
WO2016069569A2 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
EP3212662B1 (en) 2014-10-27 2020-04-08 Danisco US Inc. Serine proteases
WO2016069544A1 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
US20170335306A1 (en) 2014-10-27 2017-11-23 Danisco Us Inc. Serine proteases
US20180010074A1 (en) 2014-10-27 2018-01-11 Danisco Us Inc. Serine proteases of bacillus species
AR102683A1 (en) 2014-11-17 2017-03-15 Procter & Gamble BENEFIT AGENT SUPPLY COMPOSITIONS
US10457921B2 (en) 2014-12-05 2019-10-29 Novozymes A/S Lipase variants and polynucleotides encoding same
US20160230124A1 (en) 2015-02-10 2016-08-11 The Procter & Gamble Company Liquid laundry cleaning composition
US20180216090A1 (en) 2015-03-12 2018-08-02 Danisco Us Inc. Compositions and methods comprising lg12-clade protease variants
JP6545822B2 (en) 2015-04-29 2019-07-17 ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company Cloth processing method
CN107548415A (en) 2015-04-29 2018-01-05 宝洁公司 The method of laundering of textile fabrics
HUE043043T2 (en) 2015-04-29 2019-07-29 Procter & Gamble Method of treating a fabric
CN112143591A (en) 2015-04-29 2020-12-29 宝洁公司 Method for treating fabric
EP3088506B1 (en) 2015-04-29 2018-05-23 The Procter and Gamble Company Detergent composition
CN111718806B (en) 2015-05-04 2022-01-04 美利肯公司 Leuco triphenylmethane colorants as bluing agents in laundry care compositions
RU2733987C2 (en) 2015-05-13 2020-10-09 ДАНИСКО ЮЭс ИНК. Versions of protease of aprl and application thereof
EP3298121B1 (en) 2015-05-19 2019-03-20 Novozymes A/S Odor reduction
EP3310908B1 (en) 2015-06-16 2020-08-05 Novozymes A/S Polypeptides with lipase activity and polynucleotides encoding same
US11499146B2 (en) 2015-06-17 2022-11-15 Danisco Us Inc. Bacillus gibsonii-clade serine proteases
WO2016205008A1 (en) 2015-06-19 2016-12-22 The Procter & Gamble Company Computer-implemeted method of making perfumed goods
EP3317407B1 (en) 2015-07-01 2021-05-19 Novozymes A/S Methods of reducing odor
CN114292829A (en) 2015-07-06 2022-04-08 诺维信公司 Lipase variants and polynucleotides encoding same
US9902923B2 (en) 2015-10-13 2018-02-27 The Procter & Gamble Company Polyglycerol dye whitening agents for cellulosic substrates
US9976035B2 (en) 2015-10-13 2018-05-22 Milliken & Company Whitening agents for cellulosic substrates
US9777250B2 (en) 2015-10-13 2017-10-03 Milliken & Company Whitening agents for cellulosic substrates
US10597614B2 (en) 2015-10-13 2020-03-24 The Procter & Gamble Company Whitening agents for cellulosic substrates
US10155868B2 (en) 2015-10-13 2018-12-18 Milliken & Company Whitening agents for cellulosic substrates
US9745544B2 (en) 2015-10-13 2017-08-29 The Procter & Gamble Company Whitening agents for cellulosic substrates
CN108603183B (en) 2015-11-05 2023-11-03 丹尼斯科美国公司 Paenibacillus species and bacillus species mannanases
EP3371308B1 (en) 2015-11-05 2022-05-11 Danisco US Inc. Paenibacillus sp. mannanases
JP2019502779A (en) 2015-11-26 2019-01-31 ザ プロクター アンド ギャンブル カンパニー Liquid detergent composition containing protease and encapsulated lipase
US10870838B2 (en) 2015-12-01 2020-12-22 Novozymes A/S Methods for producing lipases
US10308900B2 (en) 2015-12-22 2019-06-04 Milliken & Company Occult particles for use in granular laundry care compositions
EP3432856A1 (en) 2016-03-24 2019-01-30 The Procter and Gamble Company Hair care compositions comprising malodor reduction compositions
JP2019518440A (en) 2016-05-03 2019-07-04 ダニスコ・ユーエス・インク Protease variant and use thereof
US20190136218A1 (en) 2016-05-05 2019-05-09 Danisco Us Inc Protease variants and uses thereof
MX2018014768A (en) 2016-05-31 2019-03-06 Danisco Us Inc Protease variants and uses thereof.
EP4151726A1 (en) 2016-06-17 2023-03-22 Danisco US Inc Protease variants and uses thereof
EP4357453A2 (en) 2016-07-18 2024-04-24 Novozymes A/S Lipase variants, polynucleotides encoding same and the use thereof
US20180119056A1 (en) 2016-11-03 2018-05-03 Milliken & Company Leuco Triphenylmethane Colorants As Bluing Agents in Laundry Care Compositions
US10577571B2 (en) 2016-11-08 2020-03-03 Ecolab Usa Inc. Non-aqueous cleaner for vegetable oil soils
US20200392477A1 (en) 2016-12-21 2020-12-17 Danisco Us Inc. Protease variants and uses thereof
WO2018118950A1 (en) 2016-12-21 2018-06-28 Danisco Us Inc. Bacillus gibsonii-clade serine proteases
EP3583210B1 (en) 2017-03-15 2021-07-07 Danisco US Inc. Trypsin-like serine proteases and uses thereof
EP3619304A1 (en) 2017-05-05 2020-03-11 Novozymes A/S Compositions comprising lipase and sulfite
CA3073362A1 (en) 2017-09-27 2019-04-04 Novozymes A/S Lipase variants and microcapsule compositions comprising such lipase variants
WO2019074993A1 (en) 2017-10-10 2019-04-18 The Procter & Gamble Company Sulfate free clear personal cleansing composition comprising low inorganic salt
CN111373039A (en) 2017-11-29 2020-07-03 丹尼斯科美国公司 Subtilisin variants having improved stability
EP3720954A1 (en) 2017-12-04 2020-10-14 Novozymes A/S Lipase variants and polynucleotides encoding same
JP2021505167A (en) 2017-12-08 2021-02-18 ノボザイムス アクティーゼルスカブ α-Amylase mutant and the polynucleotide encoding it
US10792384B2 (en) 2017-12-15 2020-10-06 The Procter & Gamble Company Rolled fibrous structures comprising encapsulated malodor reduction compositions
CN111868239A (en) 2018-02-08 2020-10-30 诺维信公司 Lipase, lipase variants and compositions thereof
WO2019154954A1 (en) 2018-02-08 2019-08-15 Novozymes A/S Lipase variants and compositions thereof
US20210214703A1 (en) 2018-06-19 2021-07-15 Danisco Us Inc Subtilisin variants
US20210363470A1 (en) 2018-06-19 2021-11-25 Danisco Us Inc Subtilisin variants
EP3833731A1 (en) 2018-08-30 2021-06-16 Danisco US Inc. Compositions comprising a lipolytic enzyme variant and methods of use thereof
WO2020068486A1 (en) 2018-09-27 2020-04-02 Danisco Us Inc Compositions for medical instrument cleaning
US11732218B2 (en) 2018-10-18 2023-08-22 Milliken & Company Polyethyleneimine compounds containing N-halamine and derivatives thereof
US20200123472A1 (en) 2018-10-18 2020-04-23 Milliken & Company Polyethyleneimine compounds containing n-halamine and derivatives thereof
US20200123475A1 (en) 2018-10-18 2020-04-23 Milliken & Company Polyethyleneimine compounds containing n-halamine and derivatives thereof
US11466122B2 (en) 2018-10-18 2022-10-11 Milliken & Company Polyethyleneimine compounds containing N-halamine and derivatives thereof
US11518963B2 (en) 2018-10-18 2022-12-06 Milliken & Company Polyethyleneimine compounds containing N-halamine and derivatives thereof
US11299591B2 (en) 2018-10-18 2022-04-12 Milliken & Company Polyethyleneimine compounds containing N-halamine and derivatives thereof
US20200123319A1 (en) 2018-10-18 2020-04-23 Milliken & Company Polyethyleneimine compounds containing n-halamine and derivatives thereof
WO2020112599A1 (en) 2018-11-28 2020-06-04 Danisco Us Inc Subtilisin variants having improved stability
CN114174504A (en) 2019-05-24 2022-03-11 丹尼斯科美国公司 Subtilisin variants and methods of use
WO2021001400A1 (en) 2019-07-02 2021-01-07 Novozymes A/S Lipase variants and compositions thereof
US11873465B2 (en) 2019-08-14 2024-01-16 Ecolab Usa Inc. Methods of cleaning and soil release of highly oil absorbing substrates employing optimized extended chain nonionic surfactants
EP4022020A1 (en) 2019-08-27 2022-07-06 Novozymes A/S Composition comprising a lipase
WO2021146255A1 (en) 2020-01-13 2021-07-22 Danisco Us Inc Compositions comprising a lipolytic enzyme variant and methods of use thereof
JP2023515118A (en) 2020-02-27 2023-04-12 ザ プロクター アンド ギャンブル カンパニー Sulfur-containing antidandruff compositions with enhanced efficacy and aesthetics
US11718814B2 (en) 2020-03-02 2023-08-08 Milliken & Company Composition comprising hueing agent
US20210269747A1 (en) 2020-03-02 2021-09-02 Milliken & Company Composition Comprising Hueing Agent
US20210277335A1 (en) 2020-03-02 2021-09-09 Milliken & Company Composition Comprising Hueing Agent
CN116075583A (en) 2020-07-06 2023-05-05 埃科莱布美国股份有限公司 Foaming mixed alcohol/water composition comprising a combination of an alkylsiloxane and a hydrotrope/solubilizer
EP4176031A1 (en) 2020-07-06 2023-05-10 Ecolab USA Inc. Peg-modified castor oil based compositions for microemulsifying and removing multiple oily soils
EP4175471A1 (en) 2020-07-06 2023-05-10 Ecolab USA Inc. Foaming mixed alcohol/water compositions comprising a structured alkoxylated siloxane
EP4237552A2 (en) 2020-10-29 2023-09-06 Novozymes A/S Lipase variants and compositions comprising such lipase variants
US20230407209A1 (en) 2020-11-13 2023-12-21 Novozymes A/S Detergent Composition Comprising a Lipase
US11819474B2 (en) 2020-12-04 2023-11-21 The Procter & Gamble Company Hair care compositions comprising malodor reduction materials
WO2022197295A1 (en) 2021-03-17 2022-09-22 Milliken & Company Polymeric colorants with reduced staining
US20220378684A1 (en) 2021-05-14 2022-12-01 The Procter & Gamble Company Shampoo Compositions Containing a Sulfate-Free Surfactant System and Sclerotium Gum Thickener
WO2023039270A2 (en) 2021-09-13 2023-03-16 Danisco Us Inc. Bioactive-containing granules
WO2023114939A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023114936A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023114932A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023116569A1 (en) 2021-12-21 2023-06-29 Novozymes A/S Composition comprising a lipase and a booster
WO2023247664A2 (en) 2022-06-24 2023-12-28 Novozymes A/S Lipase variants and compositions comprising such lipase variants
US20240026248A1 (en) 2022-07-20 2024-01-25 Ecolab Usa Inc. Novel nonionic extended surfactants, compositions and methods of use thereof
WO2024050339A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Mannanase variants and methods of use
WO2024050343A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Subtilisin variants and methods related thereto
WO2024050346A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Detergent compositions and methods related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2448261A1 (en) * 1997-03-07 1998-09-11 The Procter & Gamble Company Improved methods of making cross-bridged macropolycycles
ZA981883B (en) * 1997-03-07 1998-09-01 Univ Kansas Catalysts and methods for catalytic oxidation

Also Published As

Publication number Publication date
JP2002531457A (en) 2002-09-24
EP1135392A2 (en) 2001-09-26
WO2000032601A3 (en) 2000-10-05
WO2000032601A2 (en) 2000-06-08
AU2026100A (en) 2000-06-19

Similar Documents

Publication Publication Date Title
CA2348893A1 (en) Process for preparing cross-bridged tetraaza macrocycles
CA2448261A1 (en) Improved methods of making cross-bridged macropolycycles
WO1994000439A1 (en) Synthesis of 1,4,7-triazacyclononane derivatives
EP0034480A2 (en) Alkylation of amines
EP0408340B1 (en) Ruthenium-optically active phoshine complex useful as catalyst
CA2544950A1 (en) Method for the catalytic production of hydrocodone and hydromorphone
WO2006103756A1 (en) Process for production of optically active quinuclidinol
US7321038B2 (en) Method for the catalytic production of hydrocodone and hydromorphone
WO2005047291A9 (en) Method for the catalytic production of hydrocodone and hydromorphone
US5159093A (en) Iridium-optically active phosphine complex and process for producing optically active alcohols using the same
MX2007011752A (en) Method for the catalytic production of hydrocodone, hydromorphone, and derivatives thereof.
CN103540625A (en) Process for the enzymatic synthesis of (7s)-1-(3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl) n-methyl methanamine, and application in the synthesis of ivabradine and salts thereof
EP0466405A1 (en) 2,2'-Bis(dicyclopenthylphosphino)-1-1'-binaphthyl and metal complexes thereof
WO2009116883A2 (en) Catalytic asymetric hydrogenation
EP1129095A1 (en) Process for preparing cross-bridged tetraaza macrocycles
US4076724A (en) Polycyclic macrocyclic compounds
AU712906B2 (en) Preparation of substituted aromatic amines
US5925790A (en) Preparation of substituted aromatic amines
JP4070444B2 (en) Process for producing unsaturated amines
JP3930922B2 (en) Dehalogenation method for halogen-substituted arylalkylamines
CN100424059C (en) Enantiomerically enriched 2-butanol
CA2250850C (en) Preparation of substituted aromatic amines
US6229035B1 (en) Preparation of substituted aromatic amines
US5210332A (en) Iridium-optically active phosphine complex and process for producing optically active alcohols using the same
CN1144795A (en) Process for preparing chloronitrobenzene acetic acid alkyl ester

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued